A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure

Circulation Research

Volumn 117, Issue 6, 2015, Pages 576-584

  Perin, Emerson C ^a   Borow, Kenneth M ^b   Silva, Guilherme V ^a   DeMaria, Anthony N ^c   Marroquin, Oscar C ^d   Huang, Paul P ^e   Traverse, Jay H ^f   Krum, Henry ^g   Skerrett, Donna ^h   Zheng, Yi ^a   Willerson, James T ^a   Itescu, Silviu ^h   Henry, Timothy D ⁱ  

^a TEXAS HEART INSTITUTE   (United States)

^b Borow Consulting Group   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

^f MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^g MONASH UNIVERSITY   (Australia)

^h Mesoblast Limited   (Australia)

ⁱ CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

heart failure; humans; myocardial infarction; stem cells

Indexed keywords

ADULT; ALLOGENEIC MESENCHYMAL PRECURSOR CELL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; EXERCISE; FEMALE; FUNCTIONAL EXERCISE CAPACITY; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE REVASCULARIZATION; HEART TAMPONADE; HEART VENTRICLE TACHYCARDIA; HOLTER MONITORING; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART FAILURE; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; NONISCHEMIC HEART FAILURE; PATIENT SAFETY; PERICARDIOCENTESIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMATOMA; AGED; ALLOTRANSPLANTATION; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; MYOCARDIAL ISCHEMIA; PROCEDURES;

AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 84937607653     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306332     Document Type: Article

References (30)

1. Gnecchi M, Zhang Z, Ni A, Dzau VJ, Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008 103 1204 1219. doi: 10.1161/CIRCRESAHA.108.176826
2. Huang NF, Li S, Mesenchymal stem cells for vascular regeneration. Regen Med 2008 3 877 892. doi: 10.2217/17460751.3.6.877
3. Psaltis PJ, Carbone A, Nelson AJ, Lau DH, Jantzen T, Manavis J, Williams K, Itescu S, Sanders P, Gronthos S, Zannettino AC, Worthley SG, Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy. JACC Cardiovasc Interv 2010 3 974 983. doi: 10.1016/j.jcin.2010.05.016
4. Gronthos S, Fitter S, Diamond P, Simmons PJ, Itescu S, Zannettino AC, A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells Dev 2007 16 953 963. doi: 10.1089/scd.2007.0069
5. Hamamoto H, Gorman JH III, Ryan LP, Hinmon R, Martens TP, Schuster MD, Plappert T, Kiupel M, St John-Sutton MG, Itescu S, Gorman RC, Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Ann Thorac Surg 2009 87 794 801. doi: 10.1016/j.athoracsur.2008.11.057
6. Psaltis PJ, Paton S, See F, Arthur A, Martin S, Itescu S, Worthley SG, Gronthos S, Zannettino AC, Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 2010 223 530 540. doi: 10.1002/jcp.22081
7. See F, Seki T, Psaltis PJ, Sondermeijer HP, Gronthos S, Zannettino AC, Govaert KM, Schuster MD, Kurlansky PA, Kelly DJ, Krum H, Itescu S, Therapeutic effects of human STRO-3-selected mesenchymal precursor cells and their soluble factors in experimental myocardial ischemia. J Cell Mol Med 2011 15 2117 2129. doi: 10.1111/j.1582-4934.2010.01241.x
8. Cheng Y, Yi G, Conditt GB, Catheter-based endomyocardial delivery of mesenchymal precursor cells using 3D echo guidance improves cardiac function in a chronic myocardial injury ovine model. Cell Transplant 2013 22 2299 2309. doi: 10.3727/096368912X658016
9. Dimmeler S, Leri A, Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008 102 1319 1330. doi: 10.1161/CIRCRESAHA.108.175943
10. Perin EC, Silva GV, Henry TD, A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). Am Heart J 2011 161 1078 87.e3. doi: 10.1016/j.ahj.2011.01.028
11. Hicks KA, James Hung HM, Mahaffey KW, Mehran R, Nissen SE, Stockbridge NL, Targum SL, Temple R, Standardized Definitions for End Point Events in Cardiovascular Trials. 2013. Accessed June 27, 2013. http://www.clinpage.com/images/uploads/endpoint-defs-11-16-2010.pdf
12. Simmons PJ, Torok-Storb B, Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991 78 55 62
13. Perin EC, Dohmann HF, Borojevic R, Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003 107 2294 2302. doi: 10.1161/01.CIR.0000070596.30552.8B
14. Perin EC, Dohmann HF, Borojevic R, Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004 110 II213 II218. doi: 10.1161/01.CIR.0000138398.77550.62
15. Perin EC, Willerson JT, Pepine CJ, Cardiovascular Cell Therapy Research Network (CCTRN) Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012 307 1717 1726. doi: 10.1001/jama.2012.418
16. Hare JM, Fishman JE, Gerstenblith G, Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012 308 2369 2379. doi: 10.1001/jama.2012.25321
17. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H, Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999 39 103 106
18. Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, Horn B, Yu L, Talano JA, Nemecek E, Mills CR, Chaudhury S, Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 2014 20 229 235. doi: 10.1016/j.bbmt.2013.11.001
19. Kastrup J, Jørgensen E, Rück A, Tägil K, Glogar D, Ruzyllo W, Bøtker HE, Dudek D, Drvota V, Hesse B, Thuesen L, Blomberg P, Gyöngyösi M, Sylvén C, Euroinject One Group Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005 45 982 988. doi: 10.1016/j.jacc.2004.12.068
20. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, Zuba-Surma EK, Al-Mallah M, Dawn B, Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007 167 989 997. doi: 10.1001/archinte.167.10.989
21. Heeschen C, Lehmann R, Honold J, Assmus B, Aicher A, Walter DH, Martin H, Zeiher AM, Dimmeler S, Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004 109 1615 1622. doi: 10.1161/01.CIR.0000124476.32871.E3
22. Baraniak PR, McDevitt TC, Stem cell paracrine actions and tissue regeneration. Regen Med 2010 5 121 143. doi: 10.2217/rme.09.74
23. Cheng AS, Yau TM, Paracrine effects of cell transplantation: strategies to augment the efficacy of cell therapies. Semin Thorac Cardiovasc Surg 2008 20 94 101. doi: 10.1053/j.semtcvs.2008.04.003
24. Ilic D, Polak J, Stem cell based therapy-where are we going? Lancet 2012 379 877 878. doi: 10.1016/S0140-6736(12)60155-X
25. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, American College of Cardiology Foundation; American Heart Association 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009 53 e1 e90. doi: 10.1016/j.jacc.2008.11.013
26. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010 56 392 406. doi: 10.1016/j.jacc.2010.05.011
27. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE, Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011 4 98 108. doi: 10.1016/j.jcmg.2010.10.008
28. McMurray JJ, Clinical practice. Systolic heart failure. N Engl J Med 2010 362 228 238. doi: 10.1056/NEJMcp0909392
29. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 2011 124 304 313. doi: 10.1161/CIRCULATIONAHA.111.022889
30. Borow KM, Neumann A, Marcus RH, Sareli P, Lang RM, Effects of simultaneous alterations in preload and afterload on measurements of left ventricular contractility in patients with dilated cardiomyopathy: comparisons of ejection phase, isovolumetric and end-systolic force-velocity indexes. J Am Coll Cardiol 1992 20 787 795